[go: up one dir, main page]

WO2012170827A3 - Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2 - Google Patents

Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2 Download PDF

Info

Publication number
WO2012170827A3
WO2012170827A3 PCT/US2012/041567 US2012041567W WO2012170827A3 WO 2012170827 A3 WO2012170827 A3 WO 2012170827A3 US 2012041567 W US2012041567 W US 2012041567W WO 2012170827 A3 WO2012170827 A3 WO 2012170827A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pyrazolopyrimidines
inhibitors
activity
related heterocycles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/041567
Other languages
English (en)
Other versions
WO2012170827A2 (fr
Inventor
Mustapha Haddach
Joe A. Tran
Fabrice Pierre
Collin F. Regan
Nicholas B. Raffaele
Suchitra Ravula
David M. Ryckman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of WO2012170827A2 publication Critical patent/WO2012170827A2/fr
Anticipated expiration legal-status Critical
Publication of WO2012170827A3 publication Critical patent/WO2012170827A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés qui inhibent l'activité de la protéine kinase CK2 (activité de CK2) et des compositions contenant de tels composés. Ces composés et compositions sont utiles pour le traitement de troubles prolifératifs tels que le cancer ainsi que d'autres états associés à la kinase incluant l'inflammation, la douleur et certains troubles immunologiques, et présentent la formule générale suivante :
PCT/US2012/041567 2011-06-08 2012-06-08 Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2 Ceased WO2012170827A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494660P 2011-06-08 2011-06-08
US61/494,660 2011-06-08

Publications (2)

Publication Number Publication Date
WO2012170827A2 WO2012170827A2 (fr) 2012-12-13
WO2012170827A3 true WO2012170827A3 (fr) 2014-05-01

Family

ID=47296763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/041567 Ceased WO2012170827A2 (fr) 2011-06-08 2012-06-08 Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2

Country Status (1)

Country Link
WO (1) WO2012170827A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155560B2 (en) 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
EP3036238A1 (fr) 2013-08-23 2016-06-29 Incyte Corporation Composés de furo- et thiéno-pyridinecarboxamide utiles en tant qu'inhibiteurs de kinases pim
KR20170003688A (ko) 2014-05-14 2017-01-09 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 단백질 탈아세틸화효소 억제제 및 이중 단백질 탈아세틸화효소-단백질 키나제 억제제로서의 헤테로사이클릭 하이드록삼산 및 그 이용 방법
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (fr) 2015-10-02 2017-04-06 Incyte Corporation Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase pim
WO2017070137A1 (fr) * 2015-10-20 2017-04-27 Bristol-Myers Squibb Company Combinaison d'inhibiteurs de ck2 et de modulateurs de points de contrôle immunitaires pour le traitement du cancer
EP3474855B1 (fr) * 2016-06-24 2022-01-26 Polaris Pharmaceuticals, Inc. Inhibiteurs de ck2, leurs compositions et méthodes associées
CN113444047B (zh) * 2016-07-20 2023-06-16 纳莹(上海)生物科技有限公司 一种荧光探针及其制备方法和用途
EP3658557B1 (fr) 2017-07-28 2024-06-05 Takeda Pharmaceutical Company Limited Inhibiteurs de tyk2 et leurs utilisations
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
MX2022008627A (es) 2020-01-13 2022-11-08 Verge Analytics Inc Pirazolo-pirimidinas sustituidas y usos de las mismas.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135581A1 (fr) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de kinases
WO2011031979A1 (fr) * 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Lactames substitués par hétérocycle pharmaceutiquement utiles
WO2011068667A1 (fr) * 2009-12-04 2011-06-09 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de ck2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135581A1 (fr) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de kinases
WO2011031979A1 (fr) * 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Lactames substitués par hétérocycle pharmaceutiquement utiles
WO2011068667A1 (fr) * 2009-12-04 2011-06-09 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de ck2

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155560B2 (en) 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
US11845754B2 (en) 2018-10-30 2023-12-19 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Also Published As

Publication number Publication date
WO2012170827A2 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012170827A3 (fr) Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
IN2012DN03112A (fr)
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
HK1210174A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
WO2015004533A3 (fr) Nouveaux composés bicycliques substitués utilisés comme inhibiteurs de bromodomaines
BR112012013508A2 (pt) pirazolopirimidinas e heterociclos relacionados como inibidores de ck2
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
EP4620528A3 (fr) Dérivés de bipyrazole en tant qu'inhibiteurs de jak
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
MX362550B (es) Inhibidores ciclicos de glutaminasa.
WO2015015318A3 (fr) Nouvelles quinazolones en tant qu'inhibiteurs de bromodomaine
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
HK1214823A1 (zh) 作為jak抑制劑的三環稠合噻吩衍生物
SG179163A1 (en) Novel tricyclic protein kinase modulators
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
WO2014080290A3 (fr) Amines cycliques servant d'inhibiteurs de bromodomaines
WO2014080291A3 (fr) Dérivés biaryle servant d'inhibiteurs de bromodomaines
EA201890768A3 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
WO2012135113A3 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12795997

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12795997

Country of ref document: EP

Kind code of ref document: A2